Denali Therapeutics (DNLI) Expected to Announce Quarterly Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Denali Therapeutics to announce earnings of ($0.5371) per share and revenue of $2.1540 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the business posted ($0.78) EPS. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Denali Therapeutics Price Performance

Shares of DNLI opened at $23.85 on Thursday. Denali Therapeutics has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The firm’s 50-day simple moving average is $22.93 and its two-hundred day simple moving average is $21.00. The stock has a market cap of $3.79 billion, a PE ratio of -8.28 and a beta of 0.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28.

Wall Street Analysts Forecast Growth

DNLI has been the subject of several recent research reports. Morgan Stanley lifted their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen raised Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Leerink Partners dropped their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $35.17.

Institutional Trading of Denali Therapeutics

Large investors have recently made changes to their positions in the stock. Headlands Technologies LLC bought a new position in Denali Therapeutics during the second quarter valued at approximately $26,000. State of Wyoming bought a new stake in Denali Therapeutics in the 2nd quarter worth approximately $29,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics in the 3rd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd purchased a new stake in Denali Therapeutics during the 4th quarter valued at $57,000. Finally, Quarry LP bought a new position in shares of Denali Therapeutics during the 3rd quarter valued at $64,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.